Ovarian cancer stage IV

5 trials 4 recruiting MedDRA PT
5 Registered trials
4 Recruiting
5 Unique sponsors
5 Unique IMPs
2 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 3
— ATC code not specified 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Monoclonal antibody (immune) 1 substance
PARP inhibitor 1 substance
Colony-stimulating factor 1 substance
Phase III: 3 Phase II: 1 Phase I (First in Human): 1

Filter these 5 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 5 trials

Phase III

3 trials
  • Tesaro Inc. Commercial
    DOSTARLIMAB; NIRAPARIB TOSILATE MONOHYDRATE
    2024-510605-28-00 13 countries 2018 n=947 Orphan
    Ended
  • Arcagy Gineco Academic
    FILGRASTIM
    2023-508260-30-01 3 countries 2024 n=145
    Recruiting
  • Ente Ospedaliero Ospedali Galliera Di Genova Academic
    LETROZOLE
    2024-516874-31-00 2 countries 2024 n=142
    Recruiting

Phase II

1 trial
  • Nord Ostdeutsche Gesellschaft Fuer Gynaekologische Onkologie e.V. Academic
    NIRAPARIB TOSILATE MONOHYDRATE
    2022-502559-69-01 6 countries 2024 n=640 Orphan
    Recruiting

Phase I (First in Human)

1 trial
  • Daiichi Sankyo Inc. Commercial
    DS-3939A
    2023-507937-14-00 3 countries 2025 n=207
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Tesaro Inc. Commercial 1 Phase III 0
Daiichi Sankyo Inc. Commercial 1 Phase I (First in Human) 1
Nord Ostdeutsche Gesellschaft Fuer Gynaekologische Onkologie e.V. Academic 1 Phase II 1
Arcagy Gineco Academic 1 Phase III 1
Ente Ospedaliero Ospedali Galliera Di Genova Academic 1 Phase III 1
New trials by year
2024
3
2025
1
← All indication landscapes